iRhythm Technologies
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 265m | 323m | 411m | 493m | 586m | 691m | 811m |
% growth | 24 % | 22 % | 27 % | 20 % | 19 % | 18 % | 17 % |
EBITDA | (42.1m) | (99.8m) | (85.1m) | (85.8m) | 22.6m | 57.1m | 104m |
% EBITDA margin | (16 %) | (31 %) | (21 %) | (17 %) | 4 % | 8 % | 13 % |
Profit | (43.8m) | (101m) | (116m) | (123m) | (93.2m) | (57.1m) | (24.1m) |
% profit margin | (17 %) | (31 %) | (28 %) | (25 %) | (16 %) | (8 %) | (3 %) |
EV / revenue | 25.6x | 10.4x | 6.4x | 6.7x | 3.8x | 3.2x | 2.7x |
EV / EBITDA | -161.4x | -33.6x | -31.0x | -38.2x | 98.5x | 39.0x | 21.1x |
R&D budget | 41.3m | 38.7m | 46.6m | 60.2m | - | - | - |
R&D % of revenue | 16 % | 12 % | 11 % | 12 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
$12.0m | Series A | ||
$6.5m | Series B | ||
$10.0m | Early VC | ||
$15.0m | Series C | ||
N/A | $7.0m | Series C | |
N/A | $22.2m | Early VC | |
N/A | $3.5m | Debt | |
$16.0m | Series D | ||
$17.0m | Series E | ||
* | N/A | $65.0m | Debt |
N/A | N/A | IPO | |
* | N/A | $115m | Post IPO Equity |
* | N/A | $220m | Post IPO Equity |
* | N/A | $575m | Post IPO Convertible |
Total Funding | €96.0m |
Related Content
Recent News about iRhythm Technologies
EditiRhythm Technologies, accessible via irhythmtech.com, is a healthcare technology company specializing in advanced cardiac monitoring solutions. Their flagship product, the Zio Patch, is a wearable device designed for extended ambulatory cardiac monitoring. This device allows for up to 14 days of uninterrupted heart rhythm tracking, providing a comprehensive view of a patient's cardiac activity. This extended monitoring period helps healthcare providers detect irregular heart rhythms that might be missed with shorter monitoring durations.
iRhythm primarily serves patients and healthcare providers. Patients who suspect they have heart rhythm issues or are at increased risk can use the Zio Patch to monitor their heart activity without the need for frequent office visits. This is particularly beneficial in the current telehealth environment, where minimizing in-person interactions is crucial due to COVID-19. Healthcare providers, including cardiologists and general practitioners, can integrate Zio into their practice to offer superior diagnostic services.
The company operates in the healthcare and medical device market, focusing on cardiac health. Their business model revolves around providing the Zio Patch to patients through healthcare providers. They generate revenue by selling the devices and related services to these providers, who then prescribe them to their patients. Additionally, iRhythm offers data analysis services, where the data collected by the Zio Patch is analyzed and interpreted, providing actionable insights to healthcare providers.
In summary, iRhythm Technologies is a key player in the cardiac monitoring space, leveraging advanced technology to improve patient outcomes and streamline healthcare workflows.
Keywords: cardiac monitoring, Zio Patch, healthcare technology, telehealth, heart rhythm, wearable device, ambulatory monitoring, patient care, healthcare providers, diagnostic services.